RedHill Biopharma Ltd.(NASDAQ: RDHL; TASE: RDHL) , today announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of type 1 diabetes, a chronic autoimmune disease with an unknown cause. In light of the preliminary positive data, and subject to the final results and an independent report expected in the coming weeks.
The Company is currently assessing the next steps in the development program, including a possible Phase II proof of concept clinical study for type 1 diabetes.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
RedHill is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer.
The pre-clinical study was designed to evaluate the potential therapeutic effects of RHB-104 using a pre-clinical diabetes model when administered orally. The preliminary data from the pre-clinical study suggests that RHB-104 is effective in treating type 1 diabetes in the study, as measured by blood glucose levels and body weight. Final results and an independent report are expected in the coming weeks.
Type 1 diabetes, previously known as juvenile diabetes, is a chronic autoimmune disease in which the pancreas produces little or no insulin, a hormone required to allow glucose to enter cells to produce energy. The disease surfaces when the body’s immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas, called beta cells.
Type 1 diabetes is typically diagnosed at a young age but can also develop in adults. There is currently no cure for type 1 diabetes and the cause of the disease is uncertain, but it is believed that both genetic factors and environmental triggers are involved.
Managing the disease is a lifelong challenge for patients, who are dependent on insulin injections or an insulin pump to control blood glucose levels. Long-term complications of type 1 diabetes develop gradually and can affect major organs including the heart, blood vessels, nerves, eyes and kidneys.
In the U.S. alone, more than 18, 000 young people are diagnosed each year with type 1 diabetes, and the worldwide sales of type 1 diabetes therapies are estimated to have exceeded $12 billion in 2013.
–
